The opioid-induced constipation treatment market size has grown strongly in recent years. It will grow from $1.66 billion in 2023 to $1.78 billion in 2024 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to increasing prevalence of opioid use, personalized OIC treatments, expanding geriatric population, availability of effective OIC drugs, and rising prevalence of gastrointestinal disorders.
The opioid-induced constipation treatment market size is expected to see strong growth in the next few years. It will grow to $2.31 billion in 2028 at a compound annual growth rate (CAGR) of 6.8%. The projected growth in the upcoming period can be credited to expedited drug approval initiatives, a rise in opioid analgesic prescription rates, heightened investment in the research and development of innovative treatments, and an uptick in biologics development. Key trends expected during this forecast period encompass initiatives aimed at educating and raising awareness among patients, the advent of targeted therapies, the implementation of non-pharmacological interventions, advancements in biotechnology, and increased investment across the sector.
The increase in opioid administration for both cancer-related and non-cancer-related pain is anticipated to drive the expansion of the market for opioid-induced constipation treatment in the future. Cancer pain pertains to discomfort associated with cancer and its treatment, while non-cancer pain refers to pain stemming from conditions unrelated to cancer. The utilization of opioids for managing pain in both cancer and non-cancer contexts is motivated by the necessity to effectively alleviate moderate to severe pain, taking into account factors such as pain intensity, duration, patient response to alternative treatments, and the overarching objective of enhancing quality of life while minimizing the risks of addiction and adverse effects. Opioid-induced constipation (OIC) treatment aids patients experiencing cancer and non-cancer pain by addressing constipation resulting from opioid use, thereby enhancing overall comfort, adherence to pain management protocols, and quality of life without compromising pain relief. For example, as of April 2023, according to data from the Centers for Disease Control and Prevention (CDC), a United States-based national public health agency, approximately 20.9% of U.S. adults (equivalent to 51.6 million individuals) reported enduring chronic pain in 2021, with 6.9% (17.1 million individuals) experiencing high-impact chronic pain, significantly impeding their daily activities. Consequently, the increase in opioid administration for both cancer and non-cancer pain is fostering the expansion of the opioid-induced constipation treatment market.
Major companies in the market for treating opioid-induced constipation are innovating mu-opioid receptor antagonists to cater to the specific requirements of patients grappling with opioid-induced constipation (OIC). Mu-opioid receptor antagonists present a focused approach to managing opioid-induced constipation, aiding patients in maintaining regular bowel movements while undergoing opioid therapy for pain relief. For example, in December 2021, Shionogi & Co. Ltd., a pharmaceutical company headquartered in Japan, secured approval for Symproic (naldemedine) tablets to treat opioid-induced constipation in adult patients in Taiwan. Symproic, a peripherally acting mu-opioid receptor antagonist, alleviates constipation stemming from opioid usage. The approval in Taiwan broadens the accessibility of Symproic as a treatment choice for OIC, extending relief to individuals grappling with this condition.
In August 2023, Grünenthal GmbH, a pharmaceutical company headquartered in Germany, finalized a joint venture partnership with Kyowa Kirin International. This collaboration encompasses a collection of 13 brands spanning six therapeutic categories, primarily focusing on pain management, which includes treatments for breakthrough cancer pain, opioid-induced constipation, and osteoporosis. Grünenthal holds a controlling 51% stake in the joint venture, with Kyowa Kirin holding the remaining 49%. Grünenthal aims to acquire the remaining 49% ownership interest at the onset of 2026. Kyowa Kirin International, based in Japan, specializes in developing medications for opioid-induced constipation, including peripherally acting mu-opioid receptor antagonists.
Major companies operating in the opioid-induced constipation treatment market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Chemical Pharma Co. Ltd., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH., Shionogi & Co. Ltd., Ono Pharmaceutical Co. Ltd., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals plc, Mundipharma International Limited, Lantheus Holdings Inc., Indivior plc, Mallinckrodt Pharmaceuticals, Collegium Pharmaceutical Inc., Ironwood Pharmaceuticals Inc., Cosmo Pharmaceuticals SA, Nektar Therapeutics, RedHill Biopharma Ltd., Theravance Biopharma Inc., Cumberland Pharmaceuticals Inc., Valinor Pharma LLC.
North America was the largest region in the opioid-induced constipation treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the opioid-induced constipation treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the opioid-induced constipation treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Opioid-induced constipation (OIC) treatment encompasses diverse methods and medications employed to address constipation resulting from opioid use. The objective of these treatments is to relieve constipation symptoms while preserving the pain-relieving benefits of opioids, thus enhancing the patient's quality of life and sustaining effective pain management through a combination of pharmacological and non-pharmacological strategies.
Drug categories for treating opioid-induced constipation comprise laxatives, peripherally acting mu-opioid receptor antagonists, serotonin receptor agonists, and prostaglandins. Laxatives are remedies utilized to stimulate bowel movements and alleviate constipation by enhancing stool frequency and softening stool consistency. They can be administered via various routes, including oral and parenteral routes such as subcutaneous injection, and are distributed through hospital pharmacies, online pharmacies, and retail pharmacies.
The opioid-induced constipation market research report is one of a series of new reports that provides opioid-induced constipation market statistics, including the opioid-induced constipation industry global market size, regional shares, competitors with opioid-induced constipation market share, detailed opioid-induced constipation market segments, market trends, and opportunities, and any further data you may need to thrive in the opioid-induced constipation industry. These opioid-induced constipation market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The opioid-induced constipation treatment market includes revenues earned by entities by providing services such as dietary and lifestyle counselling, medical consultation, diagnostic and telehealth services. The market value includes the value of related goods sold by the service provider or included within the service offering. The opioid-induced constipation treatment market also includes sales of injections, tablets, syrups, lubricants, fibre supplements, enemas, suppositories and probiotics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The opioid-induced constipation treatment market size is expected to see strong growth in the next few years. It will grow to $2.31 billion in 2028 at a compound annual growth rate (CAGR) of 6.8%. The projected growth in the upcoming period can be credited to expedited drug approval initiatives, a rise in opioid analgesic prescription rates, heightened investment in the research and development of innovative treatments, and an uptick in biologics development. Key trends expected during this forecast period encompass initiatives aimed at educating and raising awareness among patients, the advent of targeted therapies, the implementation of non-pharmacological interventions, advancements in biotechnology, and increased investment across the sector.
The increase in opioid administration for both cancer-related and non-cancer-related pain is anticipated to drive the expansion of the market for opioid-induced constipation treatment in the future. Cancer pain pertains to discomfort associated with cancer and its treatment, while non-cancer pain refers to pain stemming from conditions unrelated to cancer. The utilization of opioids for managing pain in both cancer and non-cancer contexts is motivated by the necessity to effectively alleviate moderate to severe pain, taking into account factors such as pain intensity, duration, patient response to alternative treatments, and the overarching objective of enhancing quality of life while minimizing the risks of addiction and adverse effects. Opioid-induced constipation (OIC) treatment aids patients experiencing cancer and non-cancer pain by addressing constipation resulting from opioid use, thereby enhancing overall comfort, adherence to pain management protocols, and quality of life without compromising pain relief. For example, as of April 2023, according to data from the Centers for Disease Control and Prevention (CDC), a United States-based national public health agency, approximately 20.9% of U.S. adults (equivalent to 51.6 million individuals) reported enduring chronic pain in 2021, with 6.9% (17.1 million individuals) experiencing high-impact chronic pain, significantly impeding their daily activities. Consequently, the increase in opioid administration for both cancer and non-cancer pain is fostering the expansion of the opioid-induced constipation treatment market.
Major companies in the market for treating opioid-induced constipation are innovating mu-opioid receptor antagonists to cater to the specific requirements of patients grappling with opioid-induced constipation (OIC). Mu-opioid receptor antagonists present a focused approach to managing opioid-induced constipation, aiding patients in maintaining regular bowel movements while undergoing opioid therapy for pain relief. For example, in December 2021, Shionogi & Co. Ltd., a pharmaceutical company headquartered in Japan, secured approval for Symproic (naldemedine) tablets to treat opioid-induced constipation in adult patients in Taiwan. Symproic, a peripherally acting mu-opioid receptor antagonist, alleviates constipation stemming from opioid usage. The approval in Taiwan broadens the accessibility of Symproic as a treatment choice for OIC, extending relief to individuals grappling with this condition.
In August 2023, Grünenthal GmbH, a pharmaceutical company headquartered in Germany, finalized a joint venture partnership with Kyowa Kirin International. This collaboration encompasses a collection of 13 brands spanning six therapeutic categories, primarily focusing on pain management, which includes treatments for breakthrough cancer pain, opioid-induced constipation, and osteoporosis. Grünenthal holds a controlling 51% stake in the joint venture, with Kyowa Kirin holding the remaining 49%. Grünenthal aims to acquire the remaining 49% ownership interest at the onset of 2026. Kyowa Kirin International, based in Japan, specializes in developing medications for opioid-induced constipation, including peripherally acting mu-opioid receptor antagonists.
Major companies operating in the opioid-induced constipation treatment market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Chemical Pharma Co. Ltd., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH., Shionogi & Co. Ltd., Ono Pharmaceutical Co. Ltd., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals plc, Mundipharma International Limited, Lantheus Holdings Inc., Indivior plc, Mallinckrodt Pharmaceuticals, Collegium Pharmaceutical Inc., Ironwood Pharmaceuticals Inc., Cosmo Pharmaceuticals SA, Nektar Therapeutics, RedHill Biopharma Ltd., Theravance Biopharma Inc., Cumberland Pharmaceuticals Inc., Valinor Pharma LLC.
North America was the largest region in the opioid-induced constipation treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the opioid-induced constipation treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the opioid-induced constipation treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Opioid-induced constipation (OIC) treatment encompasses diverse methods and medications employed to address constipation resulting from opioid use. The objective of these treatments is to relieve constipation symptoms while preserving the pain-relieving benefits of opioids, thus enhancing the patient's quality of life and sustaining effective pain management through a combination of pharmacological and non-pharmacological strategies.
Drug categories for treating opioid-induced constipation comprise laxatives, peripherally acting mu-opioid receptor antagonists, serotonin receptor agonists, and prostaglandins. Laxatives are remedies utilized to stimulate bowel movements and alleviate constipation by enhancing stool frequency and softening stool consistency. They can be administered via various routes, including oral and parenteral routes such as subcutaneous injection, and are distributed through hospital pharmacies, online pharmacies, and retail pharmacies.
The opioid-induced constipation market research report is one of a series of new reports that provides opioid-induced constipation market statistics, including the opioid-induced constipation industry global market size, regional shares, competitors with opioid-induced constipation market share, detailed opioid-induced constipation market segments, market trends, and opportunities, and any further data you may need to thrive in the opioid-induced constipation industry. These opioid-induced constipation market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The opioid-induced constipation treatment market includes revenues earned by entities by providing services such as dietary and lifestyle counselling, medical consultation, diagnostic and telehealth services. The market value includes the value of related goods sold by the service provider or included within the service offering. The opioid-induced constipation treatment market also includes sales of injections, tablets, syrups, lubricants, fibre supplements, enemas, suppositories and probiotics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Opioid-Induced Constipation Treatment Market Characteristics3. Opioid-Induced Constipation Treatment Market Trends And Strategies32. Global Opioid-Induced Constipation Treatment Market Competitive Benchmarking33. Global Opioid-Induced Constipation Treatment Market Competitive Dashboard34. Key Mergers And Acquisitions In The Opioid-Induced Constipation Treatment Market
4. Opioid-Induced Constipation Treatment Market - Macro Economic Scenario
5. Global Opioid-Induced Constipation Treatment Market Size and Growth
6. Opioid-Induced Constipation Treatment Market Segmentation
7. Opioid-Induced Constipation Treatment Market Regional And Country Analysis
8. Asia-Pacific Opioid-Induced Constipation Treatment Market
9. China Opioid-Induced Constipation Treatment Market
10. India Opioid-Induced Constipation Treatment Market
11. Japan Opioid-Induced Constipation Treatment Market
12. Australia Opioid-Induced Constipation Treatment Market
13. Indonesia Opioid-Induced Constipation Treatment Market
14. South Korea Opioid-Induced Constipation Treatment Market
15. Western Europe Opioid-Induced Constipation Treatment Market
16. UK Opioid-Induced Constipation Treatment Market
17. Germany Opioid-Induced Constipation Treatment Market
18. France Opioid-Induced Constipation Treatment Market
19. Italy Opioid-Induced Constipation Treatment Market
20. Spain Opioid-Induced Constipation Treatment Market
21. Eastern Europe Opioid-Induced Constipation Treatment Market
22. Russia Opioid-Induced Constipation Treatment Market
23. North America Opioid-Induced Constipation Treatment Market
24. USA Opioid-Induced Constipation Treatment Market
25. Canada Opioid-Induced Constipation Treatment Market
26. South America Opioid-Induced Constipation Treatment Market
27. Brazil Opioid-Induced Constipation Treatment Market
28. Middle East Opioid-Induced Constipation Treatment Market
29. Africa Opioid-Induced Constipation Treatment Market
30. Opioid-Induced Constipation Treatment Market Competitive Landscape And Company Profiles
31. Opioid-Induced Constipation Treatment Market Other Major And Innovative Companies
35. Opioid-Induced Constipation Treatment Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Opioid-Induced Constipation Treatment Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on opioid-induced constipation treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for opioid-induced constipation treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The opioid-induced constipation treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Drug Class: Laxatives; Peripherally Acting μ-opioid Receptor Antagonists; Serotonin Receptor Agonists; Prostaglandin2) By Type: Oral; Parenteral
3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies
Key Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Bayer AG; Sanofi S.A.; AstraZeneca plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Pfizer Inc.
- Merck & Co. Inc.
- Bayer AG
- Sanofi S.A.
- AstraZeneca plc
- Takeda Pharmaceutical Company Limited
- Daiichi Sankyo Chemical Pharma Co. Ltd.
- Bausch Health Companies Inc.
- Boehringer Ingelheim International GmbH.
- Shionogi & Co. Ltd.
- Ono Pharmaceutical Co. Ltd.
- Dr. Reddy's Laboratories Ltd.
- Hikma Pharmaceuticals plc
- Mundipharma International Limited
- Lantheus Holdings Inc.
- Indivior plc
- Mallinckrodt Pharmaceuticals
- Collegium Pharmaceutical Inc.
- Ironwood Pharmaceuticals Inc.
- Cosmo Pharmaceuticals SA
- Nektar Therapeutics
- RedHill Biopharma Ltd.
- Theravance Biopharma Inc.
- Cumberland Pharmaceuticals Inc.
- Valinor Pharma LLC
